Pharmaceuticals and Healthcare

Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2016 $2500

Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2016 Summary GlobalData’s clinical trial report, “Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2016″ provides an overview of Chronic ...Read the full article

15th June, 2016 • GlobalData

 

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2016 $2500

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2016 Summary GlobalData’s clinical trial report, “Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, ...Read the full article

15th June, 2016 • GlobalData

 

Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H1, 2016 $2500

Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H1, 2016 Summary GlobalData’s clinical trial report, “Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H1, 2016″ provides an overview of Chemotherapy ...Read the full article

15th June, 2016 • GlobalData

 

Chemotherapy Induced Anemia Global Clinical Trials Review, H1, 2016 $2500

Chemotherapy Induced Anemia Global Clinical Trials Review, H1, 2016 Summary GlobalData’s clinical trial report, “Chemotherapy Induced Anemia Global Clinical Trials Review, H1, 2016″ provides an overview of Chemotherapy Induced Anemia ...Read the full article

15th June, 2016 • GlobalData

 

Brenner Tumor Global Clinical Trials Review, H1, 2016 $2500

Brenner Tumor Global Clinical Trials Review, H1, 2016 Summary GlobalData’s clinical trial report, “Brenner Tumor Global Clinical Trials Review, H1, 2016″ provides an overview of Brenner Tumor clinical trials scenario. ...Read the full article

15th June, 2016 • GlobalData

 

Choriocarcinoma (Gestational Trophoblastic Neoplasia) Global Clinical Trials Review, H1, 2016 $2500

Choriocarcinoma (Gestational Trophoblastic Neoplasia) Global Clinical Trials Review, H1, 2016 Summary GlobalData’s clinical trial report, “Choriocarcinoma (Gestational Trophoblastic Neoplasia) Global Clinical Trials Review, H1, 2016″ provides an overview of Choriocarcinoma ...Read the full article

15th June, 2016 • GlobalData

 

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Global Clinical Trials Review, H1, 2016 $2500

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Global Clinical Trials Review, H1, 2016 Summary GlobalData’s clinical trial report, “Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Global Clinical Trials Review, H1, ...Read the full article

15th June, 2016 • GlobalData

 

Cutaneous B-Cell Lymphoma Global Clinical Trials Review, H1, 2016 $2500

Cutaneous B-Cell Lymphoma Global Clinical Trials Review, H1, 2016 Summary GlobalData’s clinical trial report, “Cutaneous B-Cell Lymphoma Global Clinical Trials Review, H1, 2016″ provides an overview of Cutaneous B-Cell Lymphoma ...Read the full article

15th June, 2016 • GlobalData

 

Chemotherapy Induced Neutropenia Global Clinical Trials Review, H1, 2016 $2500

Chemotherapy Induced Neutropenia Global Clinical Trials Review, H1, 2016 Summary GlobalData’s clinical trial report, “Chemotherapy Induced Neutropenia Global Clinical Trials Review, H1, 2016″ provides an overview of Chemotherapy Induced Neutropenia ...Read the full article

15th June, 2016 • GlobalData

 

High-Grade Glioma Global Clinical Trials Review, H1, 2016 $2500

High-Grade Glioma Global Clinical Trials Review, H1, 2016 Summary GlobalData’s clinical trial report, “High-Grade Glioma Global Clinical Trials Review, H1, 2016″ provides an overview of High-Grade Glioma clinical trials scenario. ...Read the full article

15th June, 2016 • GlobalData

 

Psoriasis – India Drug Forecast and Market Analysis to 2024 $4995

Psoriasis – India Drug Forecast and Market Analysis to 2024 Summary Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. ...Read the full article

13th April, 2016 • GlobalData

 

Psoriasis – Japan Drug Forecast and Market Analysis to 2024 $4995

Psoriasis – Japan Drug Forecast and Market Analysis to 2024 Summary Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. ...Read the full article

13th April, 2016 • GlobalData

 

Psoriasis – US Drug Forecast and Market Analysis to 2024 $4995

Psoriasis – US Drug Forecast and Market Analysis to 2024 Summary Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. ...Read the full article

13th April, 2016 • GlobalData

 

Psoriasis – 5EU Drug Forecast and Market Analysis to 2024 $6995

Psoriasis – 5EU Drug Forecast and Market Analysis to 2024 Summary Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. ...Read the full article

13th April, 2016 • GlobalData

 

Psoriasis – Current and Future Players $2995

Psoriasis – Current and Future Players Summary GlobalData has released its pharma report, “Psoriasis – Current and Future Players”. The report is a vital source of up-to-date information with in-depth ...Read the full article

13th April, 2016 • GlobalData

 

PharmaPoint: Psoriasis – Global Drug Forecast and Market Analysis to 2024 $10995

PharmaPoint: Psoriasis – Global Drug Forecast and Market Analysis to 2024 Summary Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% ...Read the full article

13th April, 2016 • GlobalData

 

EpiCast Report: Bipolar Disorder – Epidemiology Forecast to 2024 $3995

EpiCast Report: Bipolar Disorder – Epidemiology Forecast to 2024 Summary Bipolar disorder, also known as bipolar depression or manic depression, is a psychological disorder that presents with severe shifts in ...Read the full article

1st March, 2016 • GlobalData

 

Partnerships, Licensing, Investments and M&A Deals and Trends for January 2016 in Pharmaceuticals $1000

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials

1st March, 2016 • GlobalData

 

PharmaPoint: Bipolar Disorder – Global Drug Forecast and Market Analysis to 2024 $10995

PharmaPoint: Bipolar Disorder – Global Drug Forecast and Market Analysis to 2024 Summary Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and ...Read the full article

1st March, 2016 • GlobalData

 

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – UK $1995

Pharmaceutical and medical device market, SWOT analysis, regulatory landscape, reimbursement landscape,Country analysis, drivers and barriers, opportunities and challenges

1st March, 2016 • GlobalData

 

Regurgitation Global Clinical Trials Review, H1, 2016 $2500

Regurgitation Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO’s, Terminated, Suspended and Withdrawn trials of Regurgitation, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.

25th February, 2016 • GlobalData

 

Mitral Regurgitation Global Clinical Trials Review, H1, 2016 $2500

Mitral Regurgitation Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO’s, Terminated, Suspended and Withdrawn trials of Mitral Regurgitation, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.

25th February, 2016 • GlobalData

 

Reperfusion Injury Global Clinical Trials Review, H1, 2016 $2500

Reperfusion Injury Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO’s, Terminated, Suspended and Withdrawn trials of Reperfusion Injury, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.

25th February, 2016 • GlobalData

 

Hypoxemia Global Clinical Trials Review, H1, 2016 $2500

Hypoxemia Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO’s, Terminated, Suspended and Withdrawn trials of Hypoxemia, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.

25th February, 2016 • GlobalData

 

Hypotension Global Clinical Trials Review, H1, 2016 $2500

Hypotension Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO’s, Terminated, Suspended and Withdrawn trials of Hypotension, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.

25th February, 2016 • GlobalData

 

Aortic Aneurysm Global Clinical Trials Review, H1, 2016 $2500

Aortic Aneurysm Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO’s, Terminated, Suspended and Withdrawn trials of Aortic Aneurysm, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.

25th February, 2016 • GlobalData

 

Osteoarthritis Global Clinical Trials Review, H1, 2016 $2500

Osteoarthritis Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO’s, Terminated, Suspended and Withdrawn trials of Osteoarthritis, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.

25th February, 2016 • GlobalData

 

Thromboembolism Global Clinical Trials Review, H1, 2016 $2500

Thromboembolism Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO’s, Terminated, Suspended and Withdrawn trials of Thromboembolism, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.

25th February, 2016 • GlobalData

 

Venous Thromboembolism Global Clinical Trials Review, H1, 2016 $2500

Venous Thromboembolism Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO’s, Terminated, Suspended and Withdrawn trials of Venous Thromboembolism, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.

25th February, 2016 • GlobalData

 

Ventricular Tachycardia Global Clinical Trials Review, H1, 2016 $2500

Ventricular Tachycardia Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO’s, Terminated, Suspended and Withdrawn trials of Ventricular Tachycardia, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.

25th February, 2016 • GlobalData

 

Let’s get started...

Broker Rating Markets Available Fees Open an Account
Kawase Logo
1 Star2 Stars3 Stars4 Stars5 Stars
Rating 3.60 /5
(15 votes cast)
Loading...
Shares, Indices, Forex and Oil Spread From 0.1 and 0.2% Commission Visit Website
Plus500 Logo
1 Star2 Stars3 Stars4 Stars5 Stars
Rating 4.48 /5
(452 votes cast)
Loading...
Stocks, Commodities, Indices and Forex. Zero commissions. No monthly fees. $10 USD fee for unused account for a period of three months. Visit Website
MaxFx Logo
1 Star2 Stars3 Stars4 Stars5 Stars
Rating 4.70 /5
(89 votes cast)
Loading...
Indices, Forex, Metals, Shares From 0.1 Raw Interbank Spread Visit Website
Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.